Patents by Inventor Yutaro Hirono

Yutaro Hirono has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
    Publication number: 20240076278
    Abstract: The present invention provides a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer including colorectal cancer. The present invention relates to a compound of formula [I-a], [I-b] or [I-c] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.
    Type: Application
    Filed: February 24, 2023
    Publication date: March 7, 2024
    Applicant: Japan Tobacco Inc.
    Inventors: Ikuo Mitani, Yutaro Hirono, Masaki Yamashita
  • HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
    Publication number: 20210024486
    Abstract: The present invention provides a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer including colorectal cancer. The present invention relates to a compound of formula [I-a], [I-b] or [I-c] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.
    Type: Application
    Filed: March 3, 2020
    Publication date: January 28, 2021
    Applicant: Japan Tobacco Inc.
    Inventors: Ikuo Mitani, Yutaro Hirono, Masaki Yamashita
  • HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
    Publication number: 20170057943
    Abstract: The present invention provides a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer including colorectal cancer. The present invention relates to a compound of formula [I-a], [I-b] or [I-c] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.
    Type: Application
    Filed: August 16, 2016
    Publication date: March 2, 2017
    Inventors: Ikuo Mitani, Yutaro Hirono, Masaki Yamashita